Most importantly, we attempted to prove the combined anti-tumor effect of nutlin-3a and apcin in MCL cells and MCL xenograft model, so as to provide the initial evidence for the clinical feasibility of dual-targeting p53 and CDC20 in MCL therapeutics. The gene discussed is CDC20; the disease is neoplasm.